mda

MDA Announces 2027 Clinical & Scientific Conference Agenda Featuring AI, Gene Therapy, Patient Data and the Latest Neuromuscular Disease Research

Four-day global conference will spotlight emerging therapies, artificial intelligence, genetic medicine, clinical trial ...
mda

Muscular Dystrophy Association Launches Nationwide Holiday Retail Campaign, Bringing Support for Families to Communities Across the Country

Annual campaign gives shoppers an opportunity to turn everyday purchases into meaningful impact for people living with muscular dystrophy, ALS and related neuromuscular diseases. NEW YORK – Wednesday, ...
mda

Muscular Dystrophy Association Names Jodi Wolff, PhD, Chief Mission Officer

The Chief Mission Officer is a newly created leadership role to strengthen MDA’s mission-driven work across the neuromuscular disease community. Most recently, Dr. Wolff served as founder of Strategic ...
mda

FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment

New York, Friday, September 11, 2026 – The Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of ...
mda

Honoring a Legacy: Dutch Bros® Annual Drink One For Dane® Day of Giving Returns to Raise ALS Awareness

Tempe, AZ., Monday, May 11, 2026 – On Friday, May 15, Dutch Bros will hold its annual Drink One for Dane Day of Giving, remembering co-founder Dane Boersma and raising awareness for amyotrophic ...
mda

FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis

New York, Friday, May 8, 2026 – The Muscular Dystrophy Association (MDA) today welcomed the U.S. Food and Drug Administration’s (FDA) approval for label expansion of VYVGART® (efgartigimod alfa-fcab) ...
mda

FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research

MDA’s research funding for Dr. Adrian Krainer’s research led to the groundbreaking discovery of SPINRAZA®. NEW YORK, Monday, March 30, 2026 – The Muscular Dystrophy Association (MDA) celebrates ...
mda

The 2026 MDA Clinical & Scientific Conference Highlights Breakthroughs in Neuromuscular Research, Innovative Therapies, and Patient Care

Orlando, FL, Thursday, March 12, 2026 – The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees from 40 countries to ...
mda

Novel exon-skipping therapies for patients with DMD: An industry update from Entrada Therapeutics

3:00 PM Discover what’s next in intracellular therapies in this 30-minute live webinar for healthcare professionals. Entrada Therapeutics’ President of Research and Development, Natarajan Sethuraman, ...
mda

Nationwide MDA Shamrocks Campaign Advances Independence for People Living with Rare Neuromuscular Conditions

Thousands of retailers will participate with in-store MDA Shamrocks pin-ups and roundups throughout February and March. New limited-edition MDA Shamrocks T-shirt, designed by volunteer MDA Board ...
mda

Muscular Dystrophy Association Supports National Launch of Champion Insights Study to Investigate ALS Risk in Fire Fighters and Other High-Performance Populations

NEW YORK, NY, Tuesday, February 4, 2026 – The Muscular Dystrophy Association (MDA) announced its support of the nationwide launch of Champion Insights, a new research initiative designed to understand ...
mda

Organizations Join Forces to Map How Human Muscle Regenerates

Muscular Dystrophy Association-led research collaboration with FSHD Society, LGMD2L Foundation, and Parent Project Muscular Dystrophy to fund Abigail Mackey, PhD, at Copenhagen University Hospital to ...